share_log

6-K: Gsk Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer

6-K: Gsk Announces First Trial Met Its Primary Endpoint of Progression Free Survival in First Line Advanced Ovarian Cancer

6-K:Gsk宣佈首項臨牀試驗達到一線晚期卵巢癌無進展生存期的主要終點
美股SEC公告 ·  2024/12/20 15:30

牛牛AI助理已提取核心訊息

GSK announced that the FIRST-ENGOT-OV44 phase III trial met its primary endpoint, demonstrating significant progression-free survival improvement in first-line advanced ovarian cancer treatment. The trial evaluated the combination of Jemperli (dostarlimab) with platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, versus standard treatment.The study involved 1,331 patients with stage III or IV nonmucinous epithelial ovarian cancer. While the primary endpoint of progression-free survival showed statistically significant improvement, the key secondary endpoint of overall survival did not meet statistical significance. The safety profile remained consistent with known profiles of individual agents.Ovarian cancer, the eighth most common cancer in women worldwide, has an 85% recurrence rate despite initial response to platinum-based chemotherapy. The trial results will be presented at an upcoming scientific meeting and shared with health authorities for further evaluation.
GSK announced that the FIRST-ENGOT-OV44 phase III trial met its primary endpoint, demonstrating significant progression-free survival improvement in first-line advanced ovarian cancer treatment. The trial evaluated the combination of Jemperli (dostarlimab) with platinum-based chemotherapy and Zejula (niraparib) maintenance, with or without bevacizumab, versus standard treatment.The study involved 1,331 patients with stage III or IV nonmucinous epithelial ovarian cancer. While the primary endpoint of progression-free survival showed statistically significant improvement, the key secondary endpoint of overall survival did not meet statistical significance. The safety profile remained consistent with known profiles of individual agents.Ovarian cancer, the eighth most common cancer in women worldwide, has an 85% recurrence rate despite initial response to platinum-based chemotherapy. The trial results will be presented at an upcoming scientific meeting and shared with health authorities for further evaluation.
GSk宣佈FIRSt-ENGOt-OV44三期試驗達到了主要終點,顯示了在一線晚期卵巢癌治療中無進展生存期的顯著改善。該試驗評估了Jemperli(多斯利單抗)與鉑金類化療以及Zejula(尼拉帕利)維持治療的組合,聯合或不聯合貝伐珠單抗,與標準治療進行比較。研究涉及1,331名患有III或IV期非粘液性上皮卵巢癌的患者。雖然無進展生存期的主要終點顯示了統計學上的顯著改善,但整體生存期的關鍵次要終點未達到統計學顯著性。安全性概況與各個藥物已知的安全性特徵保持一致。卵巢癌是全球女性中第八常見的癌症,儘管在鉑金類化療的初始反應後,其複發率仍高達85%。試驗結果將在即將舉行的科學會議上發佈,並與衛生當局分享以便進一步評估。
GSk宣佈FIRSt-ENGOt-OV44三期試驗達到了主要終點,顯示了在一線晚期卵巢癌治療中無進展生存期的顯著改善。該試驗評估了Jemperli(多斯利單抗)與鉑金類化療以及Zejula(尼拉帕利)維持治療的組合,聯合或不聯合貝伐珠單抗,與標準治療進行比較。研究涉及1,331名患有III或IV期非粘液性上皮卵巢癌的患者。雖然無進展生存期的主要終點顯示了統計學上的顯著改善,但整體生存期的關鍵次要終點未達到統計學顯著性。安全性概況與各個藥物已知的安全性特徵保持一致。卵巢癌是全球女性中第八常見的癌症,儘管在鉑金類化療的初始反應後,其複發率仍高達85%。試驗結果將在即將舉行的科學會議上發佈,並與衛生當局分享以便進一步評估。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 278

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。